NEW YORK (GenomeWeb) – OncoCyte shared data this week from the latest validation and optimization of its blood-based lung cancer test, showing that the test meets the expected sensitivity and specificity thresholds for the firm to launch commercially this year as planned.
OncoCyte's test is designed as a as a confirmatory tool — used after a lung nodule is discovered via radiologic imaging to help pick out patients who can avoid further interventions like a tissue biopsy.